Bekkhan Khatsiev

Bekkhan Khatsiev

Auto-generated profile, based on publicly available information

Bekkhan Khatsiev

Stavropol State Medical University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2016 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
AKAlexandr Kuzminov
Alexandr Kuzminov
APAndrew J. Palmer
Andrew J. Palmer
SWStephen Wilkinson
Stephen Wilkinson
BKBekkhan Khatsiev
Bekkhan Khatsiev
AVAlison J. Venn
Alison J. Venn

15 July 2025 in Bulletin of Reproductive Health
Verified
Journal Article
Open access
PDF file
IDI. I. Dedov
I. I. Dedov
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
GMG. A. Melnichenko
G. A. Melnichenko
ETEkaterina Troshina
Ekaterina Troshina
NMN. V. Mazurina
N. V. Mazurina
ЮХЮ. Ш. Халимов
Ю. Ш. Халимов
Клинические рекомендации «Ожирение» Минздрава России. Версия 2024 года

13 February 2025 in Endoscopic Surgery
Verified
Journal Article
Closed access
ANA.E. Neimark
A.E. Neimark
YYYu.I. Yashkov
Yu.I. Yashkov
BKB.B. Khatsiev
B.B. Khatsiev
VAV.V. Anishchenko
V.V. Anishchenko
VSV.S. Samoylov
V.S. Samoylov
ASA.S. Shulyakovskaya
A.S. Shulyakovskaya
Obesity remains one of the global problems of modern healthcare. Complications after bariatric surgery are a serious problem for this group of patients. This article reflects the results of the Second Consensus Conference, held on May 25, 2024 in St. Petersburg and fully devoted to the treatment of complications in bariatric patients. 99 bariatric surgeons participated in the consensus. Consensus was considered achieved when 70% of respondents agreed. The consensus determines the algorithm of actions in the development of complications in a bariatric patient and will allow surgeons who do not have specialized training and experience in the management of bariatric patients to provide effective and timely treatment.

6 March 2025 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
KMK.I. Matrenin
K.I. Matrenin
EKE.O. Kurilovich
E.O. Kurilovich
BKB.B. Khatsiev
B.B. Khatsiev
RTR.A. Teryan
R.A. Teryan
ISI.V. Sorokovikov
I.V. Sorokovikov
Ratio Objective. To perform cost-effectiveness analysis of bariatric surgery in adult obese patients compared to standard drug therapy; to analyze the impact of bariatric surgery on national budget system from the perspective of the healthcare system and the state. Material and methods. The mathematical model assessed clinical and economic effectiveness of two treatment methods: bariatric surgery vs. standard drug therapy in obese adult patients with BMI ≥40 kg/m2 regardless of comorbidities and obese adults with BMI ≥35 kg/m2 and comorbidities (diabetes mellitus type 2, joint diseases, obstructive sleep apnea syndrome). The model was used to predict all-cause mortality. Direct costs of treating obesity, other direct and indirect costs following losses in gross domestic product due to mortality of working-age population, as well as total costs and break-even point, incremental cost-effectiveness ratio (ICER) were calculated. The budget impact of bariatric surgery was analyzed. Results. We found higher cost and clinical efficacy of bariatric surgery compared to standard drug therapy for obesity. After bariatric surgery, mortality was lower by 20.65% in the first year and 45.69% in the seventh year compared to standard drug therapy. Bariatric surgery is characterized by higher costs related to surgical intervention. The last ones occurred at the beginning of modeling. Cost of therapy increased over time and spread over the entire modeling horizon. The cost per case of bariatric surgery was 303.574.00 rubles, standard drug therapy for obesity — 73.006.13 rubles per year, and these values increased over time. In turn, the total costs, including the costs of treating obesity, other direct costs, as well as indirect costs were significantly lower in the bariatric surgery group. In long-term period, this significantly reduced economic burden of the state on the treatment of morbid obesity by 30.84% and 63.12% without discounting over a 5-year and 7-year horizon, respectively. Taking into account obesity treatment cost, other direct and indirect costs, we achieved break-even point at the 86th, 56th and 45th month of modeling, respectively. Conclusion. Bariatric surgery in patients with morbid obesity can reduce the number of deaths. Additional one-time direct costs will be compensated over time due to higher cumulative cost of drug therapy, other direct and indirect costs for patients receiving drug therapy with possible break-even point after 45—86 months.

20 February 2026 in Endoscopic Surgery
Verified
Journal Article
Closed access
VSV.V. Strizheletsky
V.V. Strizheletsky
ESE.A. Spichakova
E.A. Spichakova
YGYulia Gomon
Yulia Gomon
MBM.A. Burikov
M.A. Burikov
ITI.O. Temnikov
I.O. Temnikov
FSF.M. Sultanova
F.M. Sultanova
Class I obesity (BMI 30—34.9 kg/m2) is a disease that causes or aggravates multiple comorbidities, shortens life expectancy, and worsens quality of life. Objective. To compare the effectiveness of sodium-glucose cotransporter type 2 (SGLT2) inhibitors and bariatric surgery in the treatment of patients with class I obesity and type 2 diabetes mellitus (T2DM) in relation to BMI dynamics, the probability of T2DM remission, the risks of heart attack, stroke, and the risks of death from all causes. Material and methods. A retrospective “case-control study” was performed. Information on the effectiveness of conservative therapy was obtained from the Webiomed predictive analytics platform, which contains anonymized electronic patient records. Information on the effectiveness of surgical treatment was obtained from the Russian National Bariatric Registry database, which contains anonymized data on patients who underwent bariatric surgery. The study assessed the dynamics of the body mass index throughout the observation period, all-cause mortality, the proportion of individuals who had a cardiovascular event and the frequency of T2DM remission. Results. Information was obtained on 47 pairs of patients. After 36 months of observation, the median BMI in the therapeutic and surgical groups was 36 kg/m2 and 25 kg/m2, respectively (p<0.01), T2DM remission was achieved by 80.8 % of the operated patients, while in the conservative therapy group, the criteria for achieving T2DM remission were not achieved in any patient (p<0.01). In the conservative therapy group, the 3-year cumulative incidence of cardiovascular events was 25.5%, in the surgical treatment group — 2% (OR 0.50, 95% CI 0.006—0.405, p=0.005). In the 3-year perspective, death from all causes occurred in 8 patients in the conservative treatment group (mortality 17%), and in 12 patients in the 8-year perspective (mortality 25.5%), in the surgical treatment group, no patient died during the 3-year follow-up period (OR 0.40, 95% CI 0.002—0.718, p=0.029). Conclusion. The obtained results emphasize the need for a wider use of bariatric interventions in the Russian Federation and their inclusion in treatment protocols for patients with class I obesity and a high risk of cardiovascular events.

3 November 2021 in Grekov's Bulletin of Surgery
Verified
Journal Article
Open access
PDF file
AKA. G. Khitaryan
A. G. Khitaryan
BKB. B. Khatsiev
B. B. Khatsiev
AMA. V. Mezhunts
A. V. Mezhunts
ASA. V. Sarkisyan
A. V. Sarkisyan
ДМД. А. Мельников
Д. А. Мельников
SBS. S. Burtcev
S. S. Burtcev
INTRODUCTION. Bariatric operations lead to changes in body composition. The desired fat loss may be accompanied by decrease of muscle mass, thus raising the risk of sarcopenia.The OBJECTIVE was to evaluate the long-term results of surgical treatment of morbid obesity and concomitant comorbid conditions, as well as a decrease of muscle mass in the pre - and long-term postoperative period.METHODS AND MATERIALS. This prospective randomized controlled blind trial included the results of treatment of 241 patients. Patients were divided into 2 groups depending on the type of surgical treatment. The first group consisted of 116 people who underwent RYGB; the second group included 125 patients who underwent OAGB/MGB. 83 patients from the first group and 95 patients from the control group at the preoperative stage and 24 months after the operation randomly underwent bioelectrical impedance with the determination of skeletal muscle mass (SMM) and skeletal muscle mass index (SMMI)=SMM/Height2. The calculated SMMI index for men normally corresponds to >10.76 kg/m2; moderate sarcopenia SMMI=8.51–10.75 kg/m2; the SMMI index of ≤8.5 kg/m2 corresponds to severe sarcopenia. For women, this index is normally ≥6.76 kg/m2; moderate – 5.76–6.75 kg/m2; severe sarcopenia ≤5.75 kg/m2. Bioelectrical impedance were performed on a «AVS-01 Medass» bioelectrical impedance body composition analyzer (Russia). RESULTS. The difference in changes in the results of anthropometric indicators, as well as laboratory indicators of diabetes compensation within 24 months in both groups was statistically insignificant (p>0.05). According to bioelectrical impedance data, the incidence of sarcopenia in patient groups was as follows: the initially normal ratio of muscle mass to the square of growth in meters, i.e. normal SMMI in 71 (85.5 %) patients in the group with RYGB, and in 78 (85.7 %) patients in the group with OAGB/MGB. Moderate sarcopenia was detected in 12 (14.5 %) patients with RYGB and 13 (14.3 %) patients with OAGB/MGB. 24 months after the operation, SMMI was distributed as follows – Norm in 59 (71.1 %) patients of the study group and 47 (51.6 %) patients in the control group. Moderate sarcopenia was found in 16 (19.3 %) patients in the group of patients with RYGB, and in 29 (31.9 %) cases in the group of patients with OAGB/MGB. Severe sarcopenia was observed in 8 (9.6 %) patients of the first group and 15 (16.5 %) patients of the second group (p=0.0001).CONCLUSIONS. Bariatric bypass surgery results in significant changes in body composition 24 months after surgery. Bioelectrical impedance allows to effectively detect these changes. The desired weight loss is associated with a significant decrease in skeletal muscle mass, mineral mass. Thus, patients after bypass surgery are at risk of sarcopenia. Sarcopenia is more pronounced in patients after OAGB/MGB than after RYGB.